Biotechnology Industry Series

About the Series

Explore the growing field of biotechnology! The School of Engineering Dean’s Office is launching a new Biotechnology Industry Series. Hear from top professionals about their career paths in biotechnology and their current work. The Biotechnology Industry Series showcases different career paths through leading voices in the field. See below for information about events in this series.

The Road to Success: Real-World Stories from a Biotech Executive

Date: Thursday, February 12, 2026
Time: 5:30 - 6:30PM (talk); 6:30 - 7:15PM (reception)
Location: Lantern, JCC 601
Speaker: Director and CEO of Cellarity Ted Myles

Interested in biotechnology? Director and CEO of Cellarity Ted Myles will share his journey to becoming a seasoned biopharma leader at “The Road to Success: Real-World Stories from a Biotech Executive.” Over the course of his career, Myles has cultivated a track record for building clinical and commercial-stage companies. Students are invited to Joyce Cummings Center Lantern Room for the first event in the series to discover more about possible futures in biotechnology. Karol Family Professor and Dean of the School of Engineering Kyongbum Lee will facilitate a conversation with Myles from 5:30-6:30PM followed by a reception with food and networking. Spots are limited.

About Ted Myles

Ted joined Cellarity in 2025 as Chief Executive Officer and a CEO-Partner at Flagship Pioneering. He is a seasoned biopharma leader with deep experience and a track record for building clinical and commercial-stage companies.

Ted was most recently at Scholar Rock, where he served as Chief Financial Officer (CFO) and Chief Operating Officer (COO). During his tenure, Myles led the company through its evolution from early development-stage through a successful Phase 3 registrational study and raised more than $1 billion in capital to advance the company’s product and pipeline strategy.

Previously, he served as CFO and COO of AMAG Pharmaceuticals, Inc. (acquired by Covis Pharmaceuticals), CFO and COO of Ocata Therapeutics, Inc. (acquired by Astellas), and CFO and Vice President of Operations at PrimeraDx, Inc. (acquired by Qiagen). Earlier in his career, Myles worked at EMD Pharmaceuticals (now EMD Serono, a part of Merck KGaA), SG Cowen Securities Corporation in the healthcare investment banking group and Coopers & Lybrand LLP.

He holds an M.B.A. from John M. Olin School of Business at Washington University in St. Louis and a B.S. in Business Administration from the University of Hartford.

Careers Outside the Lab from Neuroscience to Patent Law: A Conversation with Dean Lee and Atsuko Polzin, EG21

Date: Wednesday, March 4, 2026
Time: 5:30 - 6:30PM (talk); 6:30 - 7:15PM (reception)
Location: Anderson Hall, Room 112 (Nelson Auditorium)
Speaker: Atsuko Polzin, EG21

Members of the Tufts community are invited to “Careers Outside the Lab from Neuroscience to Patent Law: A Conversation with Dean Lee and Atsuko Polzin, EG21." After studying neuroscience at Tufts University, Polzin made a career switch to patent law. Hear more about how she navigated this career move and her advice for students. Karol Family Professor and Dean of the School of Engineering Kyongbum Lee will facilitate the conversation in Nelson Auditorium (Anderson Hall, Room 112) from 5:30 - 6:30PM. Reception to follow from 6:30 - 7:15PM in Burden Lounge. Spots are limited.

About Atsuko Polzin

Dr. Polzin, EG21, has a Ph.D. in Neuroscience from Tufts University, where she studied the role of Ral small GTPases in the modulation of synaptic transmission. Following postdoctoral training, she made a career decision to pursue patent law. She obtained a law degree from Suffolk University Law School, while working as a technology specialist at a Boston-based IP boutique law firm. After practicing law at Choate, Hall and Stewart, a premier general practice law firm with a strong IP practice group in Boston, where she leveraged her scientific expertise to create value in the form of intellectual property for a number of biopharmaceutical and academic clients, she transitioned to an in-house position at Novartis, then to Scholar Rock, where she is currently Senior Vice President and Head of Intellectual Property.